FDA clears IND for Forazapadin – The second FSHD program financed by patients this year
A candidate FSHD therapy is moving into the clinic, and a patient organization helped put it there. It is the second time this has happened in three months. On 24 September 2026, the U.S. Food and Drug Administration cleared an Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy.